Olverembatinib, an investigational multikinase inhibitor (approved in China for CML), inhibits Src-family kinases (e.g., Lyn, ...

Bristol Myers’ BMY CAR T cell therapy Breyanzi (lisocabtagene maraleucel; liso-cel) posted strong growth in 2025. Breyanzi is ...

Explore 2026 CLL frontline choices, from all-oral acalabrutinib–venetoclax to MRD-guided care, plus pipeline advances and ...

Researchers say study lays groundwork for tailored sex-specific strategies to monitor and improve immune health across lifespan.

Eli Lilly and Co. LLY shares were little changed in Monday’s premarket session. The U.S. drug giant shared results from the ...

Enrolling Phase 2 DAYBreak CLL-201 bexobrutideg trial designed to support Accelerated Approval in relapsed/refractory chronic lymphocytic ...

For decades, people diagnosed with CLL or SLL have often faced the reality of long-term or even lifelong cancer treatments, as these slow-growing cancers tend to recur frequently, requiring additional ...

What Is It, and Why Does It Matter? The FDA has approved a new combination treatment for adults with certain cancers of the blood and lymphatic system. The targeted regimen combines Calquence ...

Blood cancer patients who receive a type of anti-cancer therapy should continue to take the drug while having COVID-19 vaccinations, a new study suggests. Research into immunotherapy against cancer ...

The U.S. Food and Drug Administration has approved an expanded indication for Eli Lilly's Jaypirca (pirtobrutinib), the first and only noncovalent Bruton tyrosine kinase (BTK) inhibitor for adults ...